Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Role of extracellular matrix signaling cues in modulating cell fate commitment for cardiovascular tissue engineering

Nakayama KH., Hou L., Huang NF.

Narrative Review on Cardiovascular Disease, published in Adv Healthc Mater (2014) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Healthc Mater (2014)
Reported sample size
—
Source database
Europe PMC
PMID
24443420
PMCID
PMC4031033
DOI
10.1002/adhm.201300620
Citations
66

Abstract (original English)

It is generally agreed that engineered cardiovascular tissues require cellular interactions with the local milieu. Within the microenvironment, the extracellular matrix (ECM) is an important support structure that provides dynamic signaling cues in part through its chemical, physical, and mechanical properties. In response to ECM factors, cells activate biochemical and mechanotransduction pathways that modulate their survival, growth, migration, differentiation, and function. This Review describes the role of ECM chemical composition, spatial patterning, and mechanical stimulation in the specification of cardiovascular lineages, with a focus on stem cell differentiation, direct transdifferentiation, and endothelial-to-mesenchymal transition. The translational application of ECMs is discussed in the context of cardiovascular tissue engineering and regenerative medicine.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
MyocardiumExtracellular MatrixMyocytes, CardiacAnimalsHumansTissue EngineeringRegenerative MedicineSignal TransductionMechanotransduction, CellularCell Differentiation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research